Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVirax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited Ordinary Shares

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.7621 USD -0.03 ( 3.76%)
Last update at 2026-11-09T15:29:00Z
VOLUME
50288
Market Cap
2.02M

Momentum Score

…

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.76
Low
0.81
High
52 Week Price Range
2.50
Low
21.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Virax Biolabs Group Limited (NASDAQ: VRAX) are limited; filings suggest it operates in the biopharmaceutical sector focused on vaccine and biologics activities. Long-term growth may be driven by clinical progress, regulatory approvals and expansion of contract manufacturing or commercial services. Investors may view the company as exposure to vaccine and biologics development if execution and financing succeed.

Material risks include limited public information, clinical and regulatory execution uncertainty, potential lack of recurring revenue or profitability, financing and dilution risk, and strong competition in vaccines and biologics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.79
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.03
Gross Profit TTM
0.01M
Debt / Equity
0.05
ROE
-78.65%
Net Debt
-6.02M
ROCE
-76.84%
Diluted EPS TTM
-12.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -5.93M -6.20M -6.74M -5.46M -1.75M
Minority interest 0.01M 0.01M 0.01M 0.00M 0.04M
Net income -5.02M -6.06M -6.73M -5.17M -1.71M
Selling general administrative 2.67M 4.33M 4.59M 5.31M 1.29M
Selling and marketing expenses - - - 0.03M 0.01M
Gross profit 0.01M -0.05M 0.05M -0.00M 0.00M
Reconciled depreciation 0.44M 0.34M 0.10M - -
Ebit -5.87M -6.15M -6.71M -5.73M -1.73M
Ebitda -5.43M -5.80M -6.61M -5.44M -1.73M
Depreciation and amortization 0.44M 0.34M 0.10M 0.29M -0.00M
Operating income -6.40M -6.16M -6.50M -5.73M -1.73M
Other operating expenses 6.41M 6.17M 6.65M 5.74M 1.73M
Interest expense 0.06M 0.06M 0.03M 0.02M 0.02M
Tax provision -0.90M -0.14M 0.00M - 0.00M
Net interest income -0.06M -0.06M -0.03M -0.02M -0.02M
Income tax expense -0.90M -0.14M -0.19M -0.29M -0.04M
Total revenue 0.01M 0.01M 0.16M 0.01M 0.00M
Total operating expenses 6.41M 6.11M 6.55M 5.73M 1.73M
Cost of revenue 0.00M 0.06M 0.11M 0.01M 0.00M
Total other income expense net 0.47M -0.04M -0.24M 0.27M -0.02M
Net income from continuing ops -5.03M -6.07M -6.74M -5.46M -1.75M
Net income applicable to common shares - - - -5.46M -1.71M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 8.32M 6.43M 5.48M 9.81M 0.05M
Intangible assets - 0.04M 0.05M 0.18M -
Other current assets 0.26M 0.54M 0.51M - 0.01M
Total liab 0.99M 0.96M 0.35M 0.91M 1.25M
Total stockholder equity 7.58M 5.70M 5.37M 9.13M -0.97M
Other current liab 0.52M 0.52M 0.06M 0.56M 0.40M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -29.61M -24.59M -18.53M -11.79M -6.34M
Cash 6.44M 4.23M 3.59M 9.35M 0.02M
Total current liabilities 0.69M 0.67M 0.17M 0.91M 1.25M
Current deferred revenue - - - 0.04M -
Net debt -6.02M -3.85M -3.36M -9.21M -0.02M
Short term debt 0.11M 0.09M 0.05M 0.15M -
Short long term debt 0.03M 0.03M - 0.15M -
Short long term debt total 0.41M 0.38M 0.22M 0.15M -
Other stockholder equity - - - 20.92M 5.36M
Total current assets 6.83M 4.89M 4.38M 9.63M 0.05M
Net tangible assets - - - 8.95M -0.97M
Short term investments 0.08M 0.09M 0.08M - -
Net receivables - 0.03M 0.22M - 0.00M
Inventory 0.05M 0.09M 0.06M 0.02M 0.02M
Accounts payable 0.05M 0.06M 0.05M 0.16M 0.85M
Accumulated other comprehensive income 37.18M 30.28M 23.89M 20.92M 5.36M
Non currrent assets other - -0.04M -0.05M - -
Non current assets total 1.50M 1.53M 1.10M 0.18M 0.00M
Capital lease obligations 0.39M 0.34M 0.22M - -
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments - -0.60M -1.16M -0.18M -
Change to liabilities - - - 0.07M 0.64M
Total cashflows from investing activities -0.26M -0.60M -1.16M -0.18M -0.18M
Net borrowings -0.11M -0.11M -0.21M 0.03M 0.19M
Total cash from financing activities 7.09M 5.81M 1.65M 13.69M 0.81M
Change to operating activities - - - -0.28M 0.00M
Net income -5.02M -6.07M -6.74M -5.46M -1.75M
Change in cash 2.21M 0.64M -5.76M 9.33M 0.00M
Begin period cash flow 4.23M 3.59M 9.35M 0.02M 0.02M
End period cash flow 6.44M 4.23M 3.59M 9.35M 0.02M
Total cash from operating activities -4.62M -4.56M -6.25M -4.18M -0.81M
Issuance of capital stock - 5.13M 0.00M 13.65M -
Depreciation 0.44M 0.34M 0.10M - -
Other cashflows from investing activities - - -0.21M - -
Change to inventory 0.09M -0.03M -0.06M 0.02M 0.00M
Change to account receivables -0.00M 0.22M -0.22M 0.00M 0.00M
Other cashflows from financing activities 4.41M 0.79M 1.85M 0.38M 0.81M
Change to netincome - - - 1.46M 0.26M
Capital expenditures 0.26M 0.60M 1.16M 0.18M 0.00M
Change in working capital 0.27M 0.63M -1.12M -0.18M 0.64M
Stock based compensation 0.13M 0.37M 1.01M 1.73M 0.29M
Other non cash items -0.44M 0.17M 0.50M -0.27M 0.01M
Free cash flow -4.88M -5.17M -7.41M -4.36M -0.81M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VRAX
Virax Biolabs Group Limited Ordinary Shares		 -0.03
3.76%		 0.76 - - 162.95 0.27 107.34 0.42
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH

44 20 7788 7414

https://viraxbiolabs.com

26

Name Title Year Born
Mr. James Foster Chairman & CEO 1987
Mr. Jason D. Davis Chief Financial Officer 1972
Mr. Cameron Lee Shaw COO & Director 1987
Mr. Mark James Ternouth Chief Technical Officer 1968
Dr. Tomasz Evan George Chief Scientific Officer 1984
Mr. James Foster Chairman & CEO 1985
Mr. Mark James Ternouth Chief Technical Officer & Director 1968
Dr. Nigel McCracken M.Sc., Ph.D. Chief Operating Officer NA
Ms. Joel Yeung Accounting Manager NA
Mr. Clement Monteil Head of Scientific Research & Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…